Harmony Biosciences Holdings Inc
HRMY32.980USD
+1.160+3.65%
收盤 11/11, 16:00（美東）報價延遲15分鐘
1.90B總市值
10.23本益比TTM
關於 Harmony Biosciences Holdings Inc 公司
Harmony Biosciences Holdings, Inc. 是一家商業階段的製藥公司。該公司專注於開發和商業化治療罕見神經系統疾病患者以及醫療需求未得到滿足的其他神經系統疾病患者的療法。其產品 WAKIX (pitolisant) 是一種首創分子，具有新穎的作用機制，旨在通過與 H3 受體結合來增強大腦中的組胺信號傳導。其 WAKIX 被開發用於治療成人發作性睡病患者的過度日間嗜睡 (EDS) 和治療成人發作性睡病患者的猝倒症。該公司還提供研究化合物 HBS-102，這是一種黑色素濃縮激素受體 1 (MCHR1) 拮抗劑，靶向大腦中的 MCH 神經元。該公司還開發了 ZYN002，一種製藥製造的合成大麻二酚。該公司還專注於擴大中樞神經系統資產後期管線中的罕見癲癇治療領域：EPX-100 和 EPX-200。
Harmony Biosciences Holdings Inc簡介
公司代碼HRMY
公司名稱Harmony Biosciences Holdings Inc
上市日期Aug 19, 2020
CEODr. Jeffrey M. (Jeff) Dayno, M.D.
員工數量- -
證券類型Ordinary Share
年結日Aug 19
公司地址630 W Germantown Pike
城市PLYMOUTH MEETING
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編19462
電話14845399800
網址https://www.harmonybiosciences.com/
公司代碼HRMY
上市日期Aug 19, 2020
CEODr. Jeffrey M. (Jeff) Dayno, M.D.
Harmony Biosciences Holdings Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Jeffrey S. (Jeff) Aronin
Mr. Jeffrey S. (Jeff) Aronin
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
251.92K
--
Dr. Kumar Budur, M.D.
Dr. Kumar Budur, M.D.
Executive Vice President and Chief Medical and Scientific Officer
Executive Vice President and Chief Medical and Scientific Officer
10.89K
+983.18%
Mr. Andrew Serafin, J.D.
Mr. Andrew Serafin, J.D.
Chief Strategy Officer
Chief Strategy Officer
1.64K
--
Mr. Adam Zaeske
Mr. Adam Zaeske
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Mr. Ron Philip
Mr. Ron Philip
Independent Director
Independent Director
--
--
Dr. Andreas Wicki, Ph.D.
Dr. Andreas Wicki, Ph.D.
Independent Director
Independent Director
--
--
Mr. R. Mark Graf
Mr. R. Mark Graf
Independent Director
Independent Director
--
--
Mr. Gary L. Sender
Mr. Gary L. Sender
Independent Director
Independent Director
--
--
Dr. Jeffrey M. (Jeff) Dayno, M.D.
Dr. Jeffrey M. (Jeff) Dayno, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Peter Anastasiou
Mr. Peter Anastasiou
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Jeffrey S. (Jeff) Aronin
Mr. Jeffrey S. (Jeff) Aronin
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
251.92K
--
Dr. Kumar Budur, M.D.
Dr. Kumar Budur, M.D.
Executive Vice President and Chief Medical and Scientific Officer
Executive Vice President and Chief Medical and Scientific Officer
10.89K
+983.18%
Mr. Andrew Serafin, J.D.
Mr. Andrew Serafin, J.D.
Chief Strategy Officer
Chief Strategy Officer
1.64K
--
Mr. Adam Zaeske
Mr. Adam Zaeske
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Mr. Ron Philip
Mr. Ron Philip
Independent Director
Independent Director
--
--
Dr. Andreas Wicki, Ph.D.
Dr. Andreas Wicki, Ph.D.
Independent Director
Independent Director
--
--
收入明細
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2022
暫無數據
地區USD
名稱
營收
佔比
United States
200.49M
0.00%
業務
地區
暫無數據
股東統計
更新時間: 9月5日 週五
更新時間: 9月5日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Marshman Fund Trust ii
10.51%
BlackRock Institutional Trust Company, N.A.
10.02%
The Vanguard Group, Inc.
8.83%
Fidelity Management & Research Company LLC
8.14%
HBM Partners AG
3.73%
其他
58.77%
持股股東
持股股東
佔比
Marshman Fund Trust ii
10.51%
BlackRock Institutional Trust Company, N.A.
10.02%
The Vanguard Group, Inc.
8.83%
Fidelity Management & Research Company LLC
8.14%
HBM Partners AG
3.73%
其他
58.77%
股東類型
持股股東
佔比
Investment Advisor
47.92%
Investment Advisor/Hedge Fund
22.47%
Corporation
10.51%
Hedge Fund
5.41%
Research Firm
4.32%
Pension Fund
1.21%
Private Equity
0.85%
Venture Capital
0.66%
Individual Investor
0.55%
其他
6.11%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
556
48.04M
83.41%
-15.75M
2025Q2
552
60.78M
105.69%
-11.17M
2025Q1
573
60.17M
104.79%
-12.54M
2024Q4
571
62.71M
109.35%
-5.92M
2024Q3
559
64.22M
112.66%
-9.33M
2024Q2
548
64.68M
113.76%
-9.02M
2024Q1
546
63.23M
110.16%
-590.81K
2023Q4
534
62.18M
105.68%
-302.40K
2023Q3
502
63.52M
115.31%
-874.73K
2023Q2
488
66.12M
110.24%
+3.64M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Marshman Fund Trust ii
6.05M
10.52%
--
--
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
5.77M
10.03%
+154.94K
+2.76%
Jun 30, 2025
The Vanguard Group, Inc.
5.10M
8.87%
+412.76K
+8.80%
Jun 30, 2025
Fidelity Management & Research Company LLC
4.69M
8.15%
-654.33K
-12.25%
Jun 30, 2025
HBM Partners AG
2.15M
3.73%
--
--
Mar 17, 2025
State Street Investment Management (US)
1.63M
2.83%
+50.21K
+3.18%
Jun 30, 2025
LSV Asset Management
1.49M
2.59%
+293.54K
+24.56%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.58M
2.75%
+357.38K
+29.18%
Jun 30, 2025
American Century Investment Management, Inc.
1.50M
2.61%
+212.63K
+16.50%
Jun 30, 2025
Marshall Wace LLP
1.21M
2.1%
+321.95K
+36.27%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月2日 週日
更新時間: 11月2日 週日
機構名稱
佔比
LSV Disciplined Value ETF
30.68%
Invesco Pharmaceuticals ETF
2.01%
SPDR S&P Pharmaceuticals ETF
1.99%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.5%
Virtus LifeSci Biotech Products ETF
1.38%
Invesco S&P SmallCap 600 GARP ETF
1.13%
Euclidean Fundamental Value ETF
1.11%
VictoryShares Small Cap Free Cash Flow ETF
0.91%
ETC 6 Meridian Small Cap Equity ETF
0.86%
Acquirers Small and Micro Deep Value ETF
0.81%
查看更多
LSV Disciplined Value ETF
佔比30.68%
Invesco Pharmaceuticals ETF
佔比2.01%
SPDR S&P Pharmaceuticals ETF
佔比1.99%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
佔比1.5%
Virtus LifeSci Biotech Products ETF
佔比1.38%
Invesco S&P SmallCap 600 GARP ETF
佔比1.13%
Euclidean Fundamental Value ETF
佔比1.11%
VictoryShares Small Cap Free Cash Flow ETF
佔比0.91%
ETC 6 Meridian Small Cap Equity ETF
佔比0.86%
Acquirers Small and Micro Deep Value ETF
佔比0.81%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
